Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.

doi:10.1002/1878-0261.13116

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.

Molecular oncology - 1 Jan 2022

Waldeck Silvia, Mitschke Jan, Wiesemann Sebastian, Rassner Michael, Andrieux Geoffroy, Deuter Max, Mutter Jurik, Lüchtenborg Anne-Marie, Kottmann Daniel, Titze Laurin, Zeisel Christoph, Jolic Martina, Philipp Ulrike, Lassmann Silke, Bronsert Peter, Greil Christine, Rawluk Justyna, Becker Heiko, Isbell Lisa, Müller Alexandra, Doostkam Soroush, Passlick Bernward, Börries Melanie, Duyster Justus, Wehrle Julius, Scherer Florian, von Bubnoff Nikolas

Abstract excerpt

Circulating tumor DNA (ctDNA) has demonstrated great potential as a noninvasive biomarker to assess minimal residual disease (MRD) and profile tumor genotypes in patients with non-small-cell lung cancer (NSCLC). However, little is known about its dynamics during and after tumor resection, or its potential for predicting clinical outcomes. Here, we applied a targeted-capture high-throughput sequencing approach to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Carcinoma, Non-Small-Cell Lung

Share to Circulating Tumor DNA

Share to High-Throughput Nucleotide Sequencing

Share to Lung Neoplasms

Share to Neoplasm Recurrence, Local

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 34653314
DOI: 10.1002/1878-0261.13116
PMCID: PMC8763652

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.PMID 34653314Read ↗

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.Semantic proximity Read ↗

Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).Semantic proximity Read ↗

Dynamic changes of circulating tumour DNA in surgical lung cancer patients: protocol for a prospective observational study.Semantic proximity Read ↗

Circulating tumor DNA detection in lung cancer patients before and after surgery.Semantic proximity Read ↗

Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction.Semantic proximity Read ↗

Molecular Residual Disease in Non‐Small Cell Lung Cancer: Technology or Patient Outcomes?Semantic proximity Read ↗

Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA FragmentomicsSemantic proximity Read ↗

Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: Evidence from a meta-analysis.Semantic proximity Read ↗

Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer.Semantic proximity Read ↗

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read ↗

Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.